Translational Therapeutics of Dipyridamole
- 1 March 2008
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 28 (3), s39-s42
- https://doi.org/10.1161/atvbaha.107.160226
Abstract
Dipyridamole (DP) is a phosphodiesterase inhibitor that increases the intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanine monophosphate (cGMP) by preventing their conversion to AMP and GMP, respectively. By increasing cAMP and cGMP levels in platelets, DP reversibly inhibits platelet aggregation and platelet-mediated thrombotic disease. In addition, DP may potentiate some of the vascular protective effects of endothelium-derived nitric oxide (NO), which increases cGMP by stimulating soluble guanylyl cyclase. Endothelium-derived NO is an important regulator of vascular tone, blood flow, and tissue perfusion. Indeed, endothelial NO synthase-deficient (eNOS −/− ) mice exhibit elevated systemic blood pressure and have larger myocardial and cerebral infarct size after ischemic injury. Other NO/cGMP-dependent effects that may be potentiated by DP include inhibition of vascular smooth muscle proliferation and prevention of endothelial-leukocyte interaction. In addition, DP increases local concentrations of adenosine and prostacyclin, which could affect vascular tone and inflammation. Finally, DP has antioxidant properties, which could stabilize platelet and vascular membranes as well as prevent the oxidation of low-density lipoprotein. These platelet and nonplatelet actions of DP may contribute to some of its therapeutic benefits in vascular disease.Keywords
This publication has 51 references indexed in Scilit:
- Modification of neutrophil adhesion to human endothelial cell line in acute ischemic stroke by dipyridamole and candesartanEuropean Journal of Neurology, 2007
- Phosphodiesterase 8 (PDE8) regulates chemotaxis of activated lymphocytesBiochemical and Biophysical Research Communications, 2006
- Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trialThe Lancet, 2006
- Role of Adenosine and Nitric Oxide on the Mechanisms of Action of DipyridamoleStroke, 2005
- Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trialThe Lancet, 2004
- Dipyridamole Enhances NO/cGMP-Mediated Vasodilator-Stimulated Phosphoprotein Phosphorylation and Signaling in Human PlateletsStroke, 2003
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- Dipyridamole–Thallium-201 Scintigraphy in the Prediction of Future Cardiac Events after Acute Myocardial InfarctionNew England Journal of Medicine, 1984
- Dipyridamole and Aspirin in Relation to Platelet Aggregation and Vessel Wall Prostaglandin GenerationJournal of Cardiovascular Pharmacology, 1982
- Leucocyte Migration Inhibitory Activity of Concanavalin‐A‐stimulated Human LymphocytesActa Medica Scandinavica, 1976